Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 1/2015

01-02-2015 | Orthopedic Management of Fractures (D Little and T Miclau, Section Editors)

Orthobiologics in the Augmentation of Osteoporotic Fractures

Authors: J. Tracy Watson, Daemeon A. Nicolaou

Published in: Current Osteoporosis Reports | Issue 1/2015

Login to get access

Abstract

Many orthobiologic adjuvants are available and widely utilized for general skeletal restoration. Their use for the specific task of osteoporotic fracture augmentation is less well recognized. Common conductive materials are reviewed for their value in this patient population including the large group of allograft adjuvants categorically known as the demineralized bone matrices (DBMs). Another large group of alloplastic materials is also examined—the calcium phosphate and sulfate ceramics. Both of these materials, when used for the proper indications, demonstrate efficacy for these patients. The inductive properties of bone morphogenic proteins (BMPs) and platelet concentrates show no clear advantages for this group of patients. Systemic agents including bisphosphonates, receptor activator of nuclear factor κβ ligand (RANKL) inhibitors, and parathyroid hormone augmentation all demonstrate positive effects with this fracture cohort. Newer modalities, such as trace ion bioceramic augmentation, are also reviewed for their positive effects on osteoporotic fracture healing.
Literature
1.
Giannoudis P et al. Fracture healing in osteoporotic fractures: is it really different? A basic science perspective. Injury. 2007;38 Suppl 1:S90–9.PubMedCrossRef
2.
Friedlaender GE. Immune responses to osteochondral allografts. Current knowledge and future directions. Clin Orthop Relat Res. 1983;174:58–68.PubMed
3.
Ramoshebi LN et al. Tissue engineering: TGF-beta superfamily members and delivery systems in bone regeneration. Expert Rev Mol Med. 2002;4(20):1–11.PubMedCrossRef
4.
5.
Moore ST et al. Osteoconductivity and osteoinductivity of Puros(R) DBM putty. J Biomater Appl. 2011;26(2):151–71.PubMedCrossRef
6.
Han B, Yang Z, Nimni M. Effects of moisture and temperature on the osteoinductivity of demineralized bone matrix. J Orthop Res. 2005;23(4):855–61.PubMedCrossRef
7.
Hierholzer C et al. Plate fixation of ununited humeral shaft fractures: effect of type of bone graft on healing. J Bone Joint Surg Am. 2006;88(7):1442–7.PubMedCrossRef
8.
Wilkins RM, Chimenti BT, Rifkin RM. Percutaneous treatment of long bone nonunions: the use of autologous bone marrow and allograft bone matrix. Orthopedics. 2003;26(5 Suppl):s549–54.PubMed
9.
Peters CL et al. Biological effects of calcium sulfate as a bone graft substitute in ovine metaphyseal defects. J Biomed Mater Res A. 2006;76(3):456–62.PubMedCrossRef
10.
11.
Beuerlein MJ, McKee MD. Calcium sulfates: what is the evidence? J Orthop Trauma. 2010;24 Suppl 1:S46–51.PubMedCrossRef
12.
Kuhne JH et al. Bone formation in coralline hydroxyapatite. Effects of pore size studied in rabbits. Acta Orthop Scand. 1994;65(3):246–52.PubMedCrossRef
13.
De Long Jr WG et al. Bone grafts and bone graft substitutes in orthopaedic trauma surgery. A critical analysis. J Bone Joint Surg Am. 2007;89(3):649–58.PubMedCrossRef
14.
Nakahara H, Goldberg VM, Caplan AI. Culture-expanded periosteal-derived cells exhibit osteochondrogenic potential in porous calcium phosphate ceramics in vivo. Clin Orthop Relat Res. 1992;276:291–8.PubMed
15.
16.
Watson JT. The use of an injectable bone graft substitute in tibial metaphyseal fractures. Orthopedics. 2004;27(1 Suppl):s103–7.PubMed
17.•
Mauffrey C et al. Incidence and pattern of technical complications in balloon-guided osteoplasty for depressed tibial plateau fractures: a pilot study in 20 consecutive patients. Patient Saf Surg. 2013;7(1):8. This study looked at the complications and steep learning curved involved with the use of inflation bone tamps to reduce depressed tibial plateau fractures.PubMedCentralPubMedCrossRef
18.
Szpalski M, Gunzburg R. Applications of calcium phosphate-based cancellous bone void fillers in trauma surgery. Orthopedics. 2002;25(5 Suppl):s601–9.PubMed
19.•
Goff T, Kanakaris NK, Giannoudis PV. Use of bone graft substitutes in the management of tibial plateau fractures. Injury. 2013;44 Suppl 1:S86–94. Review of 19 studies comparing various bone graft substitutes which showed greater tolerance of early weight bearing and improved early functional outcomes with injectable calcium phosphate.PubMedCrossRef
20.
Bajammal SS et al. The use of calcium phosphate bone cement in fracture treatment. A meta-analysis of randomized trials. J Bone Joint Surg Am. 2008;90(6):1186–96.PubMedCrossRef
21.•
Kim JK, Koh YD, Kook SH. Effect of calcium phosphate bone cement augmentation on volar plate fixation of unstable distal radial fractures in the elderly. J Bone Joint Surg Am. 2011;93(7):609–14. Augmentation of metaphyseal defects with calcium phosphate bone cement after volar locking plate fixation offered no benefit over volar locking plate fixation alone in elderly patients with an unstable distal radial fracture.PubMedCrossRef
22.
Suhm N, Gisep A. Injectable bone cement augmentation for the treatment of distal radius fractures: a review. J Orthop Trauma. 2008;22(8 Suppl):S121–5.PubMedCrossRef
23.
Lindner T et al. Fractures of the hip and osteoporosis: the role of bone substitutes. J Bone Joint Surg (Br). 2009;91(3):294–303.CrossRef
24.
Sanchez AR, Sheridan PJ, Kupp LI. Is platelet-rich plasma the perfect enhancement factor? A current review. Int J Oral Maxillofac Implants. 2003;18(1):93–103.PubMed
25.
Friedlaender GE et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg AmSuppl. 2001;83(A Suppl 1(Pt 2)):S151–8.
26.
Blokhuis TJ, Calori GM, Schmidmaier G. Autograft versus BMPs for the treatment of non-unions: what is the evidence? Injury. 2013;44 Suppl 1:S40–2.PubMedCrossRef
27.•
Lad SP et al. Cancer after spinal fusion: the role of bone morphogenetic protein. Neurosurgery. 2013;73(3):440–9. This study showed increased incidence of benign tumors especially of the nervous system in lumbar fusion patients exposed to BMP.PubMedCrossRef
28.
Morris CD, Einhorn TA. Bisphosphonates in orthopaedic surgery. J Bone Joint Surg Am. 2005;87(7):1609–18.PubMedCrossRef
29.
Amanat N et al. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res. 2007;22(6):867–76.PubMedCrossRef
30.
Lyles KW et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799–809.PubMedCrossRef
31.
Li J et al. Concentration of bisphosphonate (incadronate) in callus area and its effects on fracture healing in rats. J Bone Miner Res. 2000;15(10):2042–51.PubMedCrossRef
32.
Amanat N et al. A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair. J Orthop Res. 2005;23(5):1029–34.PubMedCrossRef
33.
Adolphson P et al. Clodronate increases mineralization of callus after Colles’ fracture: a randomized, double-blind, placebo-controlled, prospective trial in 32 patients. Acta Orthop Scand. 2000;71(2):195–200.PubMedCrossRef
34.
Schmidt GA et al. Risks and benefits of long-term bisphosphonate therapy. Am J Health Syst Pharm. 2010;67(12):994–1001.PubMedCrossRef
35.
Watts NB. Long-term risks of bisphosphonate therapy. Arq Bras Endocrinol Metabol. 2014;58(5):523–9.PubMedCrossRef
36.
37.
Janovska Z. Bisphosphonate-related osteonecrosis of the jaws. A severe side effect of bisphosphonate therapy. Acta Med (Hradec Kralove). 2012;55(3):111–5.
38.
Egol KA et al. Healing delayed but generally reliable after bisphosphonate-associated complete femur fractures treated with IM nails. Clin Orthop Relat Res. 2014;472(9):2728–34.PubMedCrossRef
39.•
Xue D et al. Do bisphosphonates affect bone healing? A meta-analysis of randomized controlled trials. J Orthop Surg Res. 2014;9:45. This recent meta-analysis looked at eight RCTs and found no delay in fracture healing with bisphosphonate therapy and recommended infusion after fracture fixation and lumbar fusion.PubMedCentralPubMedCrossRef
40.
Moroni A et al. Alendronate improves screw fixation in osteoporotic bone. J Bone Joint Surg Am. 2007;89(1):96–101.PubMedCrossRef
41.
Moen MD, Keam SJ. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging. 2011;28(1):63–82.PubMedCrossRef
42.
Cummings SR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.PubMedCrossRef
43.•
Adami S et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am. 2012;94(23):2113–9. The three year results of this placebo-controlled trial showed no evidence of impaired healing in 303 patients treated with 60mg Denosumab showed no delay in fracture healing or increased complications even when administered immediately after surgery.PubMedCrossRef
44.
Flick LM et al. Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. J Orthop Res. 2003;21(4):676–84.PubMedCrossRef
45.
Ulrich-Vinther M, Andreassen TT. Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength. Calcif Tissue Int. 2005;76(4):280–6.PubMedCrossRef
46.
Wu CC et al. Enhanced healing of sacral and pubic insufficiency fractures by teriparatide. J Rheumatol. 2012;39(6):1306–7.PubMedCrossRef
47.
Alkhiary YM et al. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am. 2005;87(4):731–41.PubMedCrossRef
48.
Nozaka K et al. Intermittent administration of human parathyroid hormone enhances bone formation and union at the site of cancellous bone osteotomy in normal and ovariectomized rats. Bone. 2008;42(1):90–7.PubMedCrossRef
49.
Rowshan HH et al. Effect of intermittent systemic administration of recombinant parathyroid hormone (1-34) on mandibular fracture healing in rats. J Oral Maxillofac Surg. 2010;68(2):260–7.PubMedCrossRef
50.
Aspenberg P et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010;25(2):404–14.PubMedCrossRef
51.
Peichl P et al. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011;93(17):1583–7.PubMedCrossRef
52.•
Zhang D et al. The role of recombinant PTH in human fracture healing: a systematic review. J Orthop Trauma. 2014;28(1):57–62. Literature review of 16 publications, the majority of which are case reports, which found no evidence of impaired fracture healing in the setting of denosumab treatment and even anecdotal evidence of enhanced fracture healing.PubMedCrossRef
53.
Jolette J et al. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol Pathol. 2006;34(7):929–40.PubMedCrossRef
54.
Vahle JL et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30(3):312–21.PubMedCrossRef
55.
Andrews EB et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012;27(12):2429–37.PubMedCentralPubMedCrossRef
56.
Bang UC, Hyldstrup L, Jensen JE. The impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporos Int. 2014;25(2):639–44.PubMedCrossRef
57.
Arcos D, Izquierdo-Barba I, Vallet-Regi M. Promising trends of bioceramics in the biomaterials field. J Mater Sci Mater Med. 2009;20(2):447–55.PubMedCrossRef
58.
Saidak Z et al. Strontium ranelate rebalances bone marrow adipogenesis and osteoblastogenesis in senescent osteopenic mice through NFATc/Maf and Wnt signaling. Aging Cell. 2012;11(3):467–74.PubMedCrossRef
59.
Peng S et al. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin. Bone. 2011;49(6):1290–8.PubMedCrossRef
60.
Yang F et al. Strontium enhances osteogenic differentiation of mesenchymal stem cells and in vivo bone formation by activating Wnt/catenin signaling. Stem Cells. 2011;29(6):981–91.PubMedCrossRef
61.
Peng S et al. Strontium promotes osteogenic differentiation of mesenchymal stem cells through the Ras/MAPK signaling pathway. Cell Phys Biochem. 2009;23:165–74.CrossRef
62.
Marie PJ, Felsenberg D, Brandi ML. How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis. Osteoporos Int. 2011;22(6):1659–67.PubMedCrossRef
63.
Saidak Z, Marie PJ. Strontium signaling: molecular mechanisms and therapeutic implications in osteoporosis. Pharmacol Ther. 2012;136(2):216–26.PubMedCrossRef
64.
Wang C et al. Osteogenesis and angiogenesis induced by porous beta-CaSiO(3)/PDLGA composite scaffold via activation of AMPK/ERK1/2 and PI3K/Akt pathways. Biomaterials. 2013;34(1):64–77.PubMedCrossRef
65.
Xu S et al. Reconstruction of calvarial defect of rabbits using porous calcium silicate bioactive ceramics. Biomaterials. 2008;29(17):2588–96.PubMedCrossRef
66.••
Lin K et al. Enhanced osteoporotic bone regeneration by strontium-substituted calcium silicate bioactive ceramics. Biomaterials. 2013;34:10028–42. These experiments demonstrated that strontium substituted calcium silicate ceramic scaffolds dramatically enhanced bone regeneration and angiogenesis in critical sized bone defects in ovarectomized mice. This paper also gave good background information on the function of strontium and silicate ions on bone metabolism and angiogenesis, respectively.PubMedCrossRef
67.
Food and Drug Administration, in Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. 1994: Rockville, USA: FDA.
Metadata
Title
Orthobiologics in the Augmentation of Osteoporotic Fractures
Authors
J. Tracy Watson
Daemeon A. Nicolaou
Publication date
01-02-2015
Publisher
Springer US
Published in
Current Osteoporosis Reports / Issue 1/2015
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-014-0249-5

Other articles of this Issue 1/2015

Current Osteoporosis Reports 1/2015 Go to the issue

Orthopedic Management of Fractures (D Little and T Miclau, Section Editors)

Internal Fixation of Osteoporotic Fractures

Skeletal Development (E Schanipani and E Zelzer, Section Editors)

Synovial Joints: from Development to Homeostasis

Orthopedic Management of Fractures (D Little and T Miclau, Section Editors)

Osteoporotic Fracture Models

Orthopedic Management of Fractures (D Little and T Miclau, Section Editors)

Fragility Fracture Programs: Are They Effective and What Is the Surgeon’s Role?

Nutrition, Exercise, and Lifestyle in Osteoporosis (CM Weaver and R Daly, Section Editors)

Lifestyle and Osteoporosis

Bone and Diabetes (AV Schwartz and P Vestergaard, Section Editors)

Diabetes Medications and Bone